To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
258 Newest Publications in future neurology
rss
Acknowledgements
03-05-2013 | Future Neurology, 2013
Future Neurology , May 2013, Vol. 8, No. 3, Pages 359-359.
Alleviating brain stress: what alternative animal models have revealed about therapeutic targets for hypoxia and anoxia
03-05-2013 | Sarah L Milton; Ken Dawson-Scully, Future Neurology, 2013
While the mammalian brain is highly dependent on oxygen, and can withstand only a few minutes without air, there are both vertebrate and invertebrate examples of anoxia tolerance. One example is the freshwater turtle, which can withstand days without oxygen, thus providing a vertebrate model ...
Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains?
03-05-2013 | Douglas G Walker; Lih-Fen Lue, Future Neurology, 2013
CD200 and its receptor, CD200 receptor (CD200R), have unique roles in controlling damaging inflammatory processes. At present, the only identified function for CD200 is as a ligand for CD200R. These proteins interact resulting in the activation of anti-inflammatory signaling by ...
Bulletin Board: Highlighting the latest news and research in neurology
03-05-2013 | Future Neurology, 2013
Future Neurology , May 2013, Vol. 8, No. 3, Pages 243-246.
The genetics of Segawa disease
03-05-2013 | Masaya Segawa, Future Neurology, 2013
Segawa disease is a dopa-responsive generalized dystonia, caused by abnormalities of the gene GCH-1 located on chromosomes 14q22.1–q22.2. Clinically, there are two types, postural type and action type, depending on the family. Cases of action type show focal or segmental dystonia after ...
Unlocking the secrets of LRRK2 function with selective kinase inhibitors
03-05-2013 | Nicolas Dzamko; Glenda M Halliday, Future Neurology, 2013
LRRK2 is currently considered to be a potential therapeutic target for the treatment of Parkinson’s disease. A number of pathological mutations, the majority of which lie in the dual catalytic domains of LRRK2, segregate with Parkinson’s disease in an autosomal-dominant fashion. The most ...
Impairment of mitochondrial dynamics: a target for the treatment of neurological disorders?
03-05-2013 | Yu-Chin Su; Xin Qi, Future Neurology, 2013
Mitochondrial dysfunction has long been appreciated in the pathogenesis of various neurological disorders. However, the molecular basis underlying the decline in mitochondrial function is not fully understood. Mitochondria are highly dynamic organelles that frequently undergo fusion and ...
Complex motor stereotypies: an evolving neurobiological concept
03-05-2013 | Sean Gao; Harvey S Singer, Future Neurology, 2013
Complex motor stereotypies are repetitive arm and/or hand flapping, waving and wiggling movements that begin before the age of 3 years, occur repeatedly throughout the day and stop with distraction. These movements are commonly seen in children with autism, but also appear in otherwise ...
Hypoxic–ischemic brain injury and neuroprotection in the newborn infant
03-05-2013 | Kyla-Anna Marks, Future Neurology, 2013
Recent clinical trials have confirmed that in term infants with moderate-to-severe hypoxic–ischemic encephalopathy, death and severe developmental disability can be reduced by early treatment with hypothermia. However, meta-analysis of these trials has confirmed that two-thirds of the ...
Dimethyl fumarate: a novel oral front-line therapy for multiple sclerosis treatment
03-05-2013 | Jack van Horssen; Helga E de Vries, Future Neurology, 2013
Owing to their immunomodulatory effects and safety profile, fumaric acid esters, such as dimethyl fumarate, are being investigated for the treatment of relapsing–remitting multiple sclerosis. BG-12, an oral formulation of dimethyl fumarate, is rapidly metabolized into its bioactive compound ...
Netmeeting
